IMM-BCP-01 + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SARS-CoV2 Infection
Conditions
SARS-CoV2 Infection, COVID-19
Trial Timeline
Jun 3, 2022 → Jan 6, 2023
NCT ID
NCT05429021About IMM-BCP-01 + Placebo
IMM-BCP-01 + Placebo is a phase 1 stage product being developed by Immunome for SARS-CoV2 Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT05429021. Target conditions include SARS-CoV2 Infection, COVID-19.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05429021 | Phase 1 | Terminated |
Competing Products
3 competing products in SARS-CoV2 Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tocilizumab 20 MG/ML | Roche | Phase 2 | 52 |
| Remdesivir | Gilead Sciences | Pre-clinical | 22 |
| VXA-CoV2-3.1 + COMIRNATY® + VXA-CoV2-3.3 | Vaxart | Phase 2 | 44 |